Home Economy Business Monod Bio Closes $25M Seed Financing to Advance Biosensor Technology Platform

Monod Bio Closes $25M Seed Financing to Advance Biosensor Technology Platform

Caption Left: The Monod Team: Chief Operating Officer, David Shoulz, Ph.D, CEO Daniel-Adriano Silva, Ph.D.and Chief Scientific Officer, Alfredo Quijano Rubio, Ph.D

Monod Bio, a life sciences company developing custom diagnostic biosensors that emit light to detect specific biomolecules of interest, has raised a $25M seed financing round. The round was led by Matrix Capital, with participation from the Global Health Investment Corporation, Cercano Management, The Washington Research Foundation, Boom Capital Ventures, Sahsen Ventures, and Pack Ventures.

Monod is using state-of-the-art computational protein design to develop a new class of modular biosensors that emit a bioluminescent signal when the sensor recognizes its target. Monod was founded in November 2021 from technology developed at David Baker’s lab at the University of Washington Institute for Protein Design. 

Biosensors are instruments that detect the presence of specific molecules, even at trace concentrations. The sensors are built from de novo engineered proteins developed using software from the Institute of Protein Design (IPD) at the University of Washington School of Medicine.

Monod has to date created biosensors that recognize the spike protein on the COVID-19 virus, cancer-receptors, and a molecule (cardiac troponin), which is released by the body after a heart attack, which was recently published in Nature. More recently, this technology was applied to the detection of COVID-19 neutralizing antibodies in vaccinated patients, Nature Biotechnology.

The new funding will be used to advance Monod’s LucCage platform for the rapid development of one-step biosensors and reporter proteins to detect targets for applications in biotechnology and medicine.

“We can now design custom biosensors that have specific functions, and this seed financing enables us to illuminate specific molecules such as viruses or biomarkers and start building prototypes that can then become real-world diagnostics,” said Daniel-Adriano Silva, Ph.D., CEO & Co-Founder, Monod Bio.

“Monod is using synthetic biology to draw on the architecture of living organisms to attain high detection sensitivity and accuracy at scale, due to low costs with biosensors compared to conventional laboratory-testing,” said Karan Takhar, Managing Partner, Matrix Capital. “Our partnership with Monod Bio reflects our commitment to back extraordinary teams unlocking breakthrough innovation at the intersection of technology and life sciences.”

“Monod is taking recent advances in computational protein engineering, and leading the field in creating highly modular biosensors to develop rapid, sensitive, and cost-effective analytical assays,” said Damien Soghoian, Partner, Global Health Investment Corporation. “With a visionary founding team and state-of-the-art technology from IPD, Monod Bio is well-positioned at the forefront of biosensor innovation and has the experience and vision to make it a reality.”